Top Stories
Check out the latest in health care reform, formulary frontlines, treatment innovations, and more in the latest issue of First Report Managed Care.
Top Stories
The momentum to establish accountable care organizations (ACOs) continues to grow, as both government and commercial payers make a push for providers to begin baring risk for patient populations. 
Top Stories
Drug costs are a top concern for voters, with polls showing that most are open to letting Medicare tackle the issue by negotiating drug prices. Here’s where the presidential candidates stand and what our experts believe are the potential...
Top Stories
The American Cancer Society's revised guidelines have inched closer to United States Preventive Services Task Force recommendations. How will this impact managed care? Our experts sort through the potential effect on Accountable Care Organizations,...
Top Stories
Is a fundamental structural issue with the exchange products overall to blame? Our experts think only time will tell. 


Single-tablet combination antiretroviral medications remain a good value for HIV-1 patients despite their cheaper generic multiple-tablet counterpa
The funding will include $920 million to expand access to medication-assisted treatment for opioid use disorders; $50 million toward access to approximately 700 substance use treatment providers, which includes medication-assisted treatment; and $30 million to evaluate the effectiveness of treatment programs and to help identify opportunities to improve treatment for opioid use disorder patients.
These 6 million Americans seem to be the people most likely to enroll, with income level making them eligible for nearly free health care services.
The two class action suits claim Group Health Cooperative and BridgeSpan limited access to treatments to those who were severely ill over financial concerns rather than for a clinical purpose. 
The report analyzes health care trends that affect retail, mail, and specialty pharmacies, including health care reform, biosimilars, the controversial 340B drug pricing program, pharmacy consolidation, manufacturers’ channel strategies, and more.


Eileen Koutnik-Fotopoulos | 2/2/2016
Payer clients are faced with alarmingly high-cost specialty drug trends with no clear direction on how to balance the dilemma of therapy versus cost. Add the explosive development of new specialty drugs over the next few years and payers will face...
Eileen Koutnik-Fotopolous | 2/2/2016
Now that the first biosimilar—filgrastim-sndz—has entered the US marketplace, policies and perceptions around these complex medicines are unfurling. With more biosimilars expected to enter the marketplace in the coming years, lingering questions...
Jill Sederstrom | 2/2/2016
As 1 of 8 states to conduct a Multi-Payer Advanced Primary Care Practice (MAPCP) demonstration project aimed to evaluate the effectiveness of patient-centered medical homes (PCMHs) when Medicaid, Medicare, and private payers support it, North...
Mary Beth Nierengarten | 2/2/2016
More than $25 billion in first-time generic drugs became available in 2015, with another $19 billion expected in 2016, according to AMCP 2015 Nexus speaker Chris Peterson, PharmD, director of emerging therapeutics, Express Scripts Holding Company....
Melissa D. Cooper | 2/2/2016
Patient behavior can be critical to health outcomes, but how can these individuals’ behavior be influenced to improve health care outcomes? Virtual health assistants, Thomas Morrow, MD, chief medical officer, Next IT, said during the second keynote...
Back to top